PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33960478-6	2021	RESULTS: Compared to pre-castration, HGS, miR-126-5p, miR-145 and miR-let7e increased significantly in horses receiving flunixin at 8 hours post-castration (Friedman test, p < 0.05).	flunixin	120-128	microRNA 126	Equus caballus	42-49
33960478-6	2021	RESULTS: Compared to pre-castration, HGS, miR-126-5p, miR-145 and miR-let7e increased significantly in horses receiving flunixin at 8 hours post-castration (Friedman test, p < 0.05).	flunixin	120-128	microRNA 145	Equus caballus	54-61
30858238-9	2019	Our results show that flunixin and 5-hydroxyflunixin are transported by ABCG2 and that this protein is responsible for their secretion into milk.	flunixin	22-30	ATP binding cassette subfamily G member 2	Bos taurus	72-77
31668307-7	2019	Our results revealed that insulin at 3 IU kg-1 as well as flunixin at 2.2 mg kg-1 can improve almost all of the physiological variables and hematobiochemical variables (including serum concentrations of tumor necrosis factor-alpha, interferon-gamma, haptoglobin, serum amyloid A, cardiac troponin I, hemocysteine, white blood cell, and packed cell volume) after 24 hours.	flunixin	58-66	interferon gamma	Equus asinus	232-248
32757313-6	2021	In recombinant P450 assays, equine CYP3A97 was the only enzyme capable of generating oxyphenbutazone while several members of the equine CYP3A family and CYP1A1 were capable of catalyzing the biotransformation of flunixin to 5-OH flunixin.	flunixin	213-221	cytochrome P450 3A97	Equus caballus	35-42
32757313-6	2021	In recombinant P450 assays, equine CYP3A97 was the only enzyme capable of generating oxyphenbutazone while several members of the equine CYP3A family and CYP1A1 were capable of catalyzing the biotransformation of flunixin to 5-OH flunixin.	flunixin	213-221	cytochrome P450 family 1 subfamily A member 1	Equus caballus	154-160
30858238-0	2019	Role of ABCG2 in Secretion into Milk of the Anti-Inflammatory Flunixin and Its Main Metabolite: In Vitro-In Vivo Correlation in Mice and Cows.	flunixin	62-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	8-13
30858238-7	2019	The objective of this work was to study the role of ABCG2 in the secretion into milk of flunixin and its main metabolite, 5-hydroxyflunixin, using Abcg2(-/-) mice, and to investigate the implication of the Y581S polymorphism in the secretion of these compounds into cow milk.	flunixin	88-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
26756424-9	2015	and flunixin (2.5 mg/kg daily, s.c.) decreased serum LDH, ALP, interleukin (IL)-1beta, and tumor necrosis factor-alpha levels, as well as colonic MPO and lipid peroxide levels, whereas increased colonic prostaglandin E2 and IL-10 concentrations were observed.	flunixin	4-12	interleukin 1 beta	Rattus norvegicus	63-85
26601710-9	2015	After 1 h injection of a dose containing 2 mg kg-1 weight pig of flunixin and tolfenamic acid to the pigs, a residue amount of 3480 +- 36 ng mL-1 and 431 +- 13 ng mL-1, respectively, was reached for the incurred pig serum specimens and both residues were reduced to about 20 ng mL-1 at the time of 24 h.	flunixin	65-73	L1 cell adhesion molecule	Mus musculus	141-167
26601710-9	2015	After 1 h injection of a dose containing 2 mg kg-1 weight pig of flunixin and tolfenamic acid to the pigs, a residue amount of 3480 +- 36 ng mL-1 and 431 +- 13 ng mL-1, respectively, was reached for the incurred pig serum specimens and both residues were reduced to about 20 ng mL-1 at the time of 24 h.	flunixin	65-73	L1 cell adhesion molecule	Mus musculus	141-145
25582761-4	2015	An additional objective was to characterize the effects of flunixin on COX-1 and COX-2 inhibition when drug concentrations reached the recommended regulatory threshold.	flunixin	59-67	cytochrome c oxidase subunit I	Equus caballus	71-76
25582761-4	2015	An additional objective was to characterize the effects of flunixin on COX-1 and COX-2 inhibition when drug concentrations reached the recommended regulatory threshold.	flunixin	59-67	cytochrome c oxidase subunit II	Equus caballus	81-86
26756424-9	2015	and flunixin (2.5 mg/kg daily, s.c.) decreased serum LDH, ALP, interleukin (IL)-1beta, and tumor necrosis factor-alpha levels, as well as colonic MPO and lipid peroxide levels, whereas increased colonic prostaglandin E2 and IL-10 concentrations were observed.	flunixin	4-12	tumor necrosis factor	Rattus norvegicus	91-118
26756424-9	2015	and flunixin (2.5 mg/kg daily, s.c.) decreased serum LDH, ALP, interleukin (IL)-1beta, and tumor necrosis factor-alpha levels, as well as colonic MPO and lipid peroxide levels, whereas increased colonic prostaglandin E2 and IL-10 concentrations were observed.	flunixin	4-12	myeloperoxidase	Rattus norvegicus	146-149
26756424-9	2015	and flunixin (2.5 mg/kg daily, s.c.) decreased serum LDH, ALP, interleukin (IL)-1beta, and tumor necrosis factor-alpha levels, as well as colonic MPO and lipid peroxide levels, whereas increased colonic prostaglandin E2 and IL-10 concentrations were observed.	flunixin	4-12	interleukin 10	Rattus norvegicus	224-229
12967936-10	2003	The COX-1 inhibitor flunixin (1 mg kg-1 i.v.)	flunixin	20-28	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	4-9
22151877-9	2012	The newer veterinary approved NSAIDs have a lower frequency of gastrointestinal adverse effects in dogs compared to drugs such as aspirin, ketoprofen and flunixin, which may be due to differential effects on the COX isoforms.	flunixin	154-162	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	212-215
20819387-9	2010	These results indicate that perioperative analgesic treatment with buprenorphine or flunixin in the CD1 mouse undergoing embryo transfer is not associated with increased embryonic loss.	flunixin	84-92	CD1 antigen complex	Mus musculus	100-103
19795941-7	2009	RESULTS: Immediately after the ischemic period, COX-2 expression in horses treated with lidocaine alone was significantly less than expression in horses treated with SS or flunixin alone.	flunixin	172-180	cytochrome c oxidase subunit II	Equus caballus	48-53
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	flunixin	61-69	cytochrome c oxidase subunit I	Equus caballus	0-5
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	flunixin	61-69	cytochrome c oxidase subunit II	Equus caballus	10-15
15939622-3	2005	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	flunixin	46-54	cytochrome c oxidase subunit II	Equus caballus	76-81
15939622-3	2005	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	flunixin	46-54	cytochrome c oxidase subunit II	Equus caballus	164-169
14705899-1	2003	The objective of this study was to establish a withdrawal period for flunixin in milk by quantifying 5-hydroxyflunixin, the marker residue, in bovine milk as a function of time, following intravenous treatment of lactating dairy cows with flunixin-N-methyl glucamine (Banamine or Finadyne).	flunixin	69-77	Weaning weight-maternal milk	Bos taurus	81-85
14705899-1	2003	The objective of this study was to establish a withdrawal period for flunixin in milk by quantifying 5-hydroxyflunixin, the marker residue, in bovine milk as a function of time, following intravenous treatment of lactating dairy cows with flunixin-N-methyl glucamine (Banamine or Finadyne).	flunixin	69-77	Weaning weight-maternal milk	Bos taurus	150-154
9049496-5	1996	Tolfenamic acid and flunixin increased the production of IL-6-like activity by LPS-stimulated synoviocytes only at the highest concentration studied (1000 mumol/l).	flunixin	20-28	interleukin 6	Equus caballus	57-61
9531514-2	1998	The purified metabolite was shown to be hydrolyzed to free flunixin by strong base and by beta-glucuronidase, suggesting the presence of a C1-beta-glucuronide ester of flunixin.	flunixin	59-67	glucuronidase beta	Canis lupus familiaris	90-108
9531514-2	1998	The purified metabolite was shown to be hydrolyzed to free flunixin by strong base and by beta-glucuronidase, suggesting the presence of a C1-beta-glucuronide ester of flunixin.	flunixin	168-176	glucuronidase beta	Canis lupus familiaris	90-108
12358053-3	2002	It was hypothesised that the nonselective COX inhibitor flunixin would retard repair of bile-injured colon by preventing production of reparative prostaglandins, whereas the selective COX-2 inhibitor, etodolac would not inhibit repair as a result of continued COX-1 activity.	flunixin	56-64	cytochrome c oxidase subunit I	Equus caballus	260-265
7653889-6	1995	Flunixin exerted inhibitory effects on serum TXB2 and exudate PGE2 concentrations, beta-glu activity, and BK-induced swelling.	flunixin	0-8	beta-glucuronidase	Bos taurus	83-91
7653889-6	1995	Flunixin exerted inhibitory effects on serum TXB2 and exudate PGE2 concentrations, beta-glu activity, and BK-induced swelling.	flunixin	0-8	kininogen 1	Bos taurus	106-108